ER-004 | Friends of Cancer Research

You are here

ER-004

Sponsor: 
Esperare
Indication: 
Investigational Prenatal Treatment ER-004 In X-Linked Hypohidrotic Ectodermal Dysplasia
Year: 
2020
Date: 
Jul 6th
FDA Status: 
Designation Granted